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Abstract
Background: Therapeutic approaches to fibromyalgia (FM) are shifting towards a 
combined multi-treatment approach to tackle the variety of symptoms experienced 
in FM. Importantly, little is known about FM patients' attitude towards the available 
treatments.
Methods: A cross-sectional web survey obtained responses from 464 individuals 
who satisfied diagnostic criteria for FM. Respondents were asked to report which 
treatments they adopted in their past, present and intend to adopt in the future. They 
also rated their level of well-being, depression, anxiety and pain catastrophizing.
Results: Data revealed a predominantly combined multi-treatment approach in a 
sample characterized by middle-aged, Caucasian women. Respondents reported per-
vasive use of pharmacological therapy but had also adopted non-pharmacological 
treatment in the past. Future intentions clustered on alternative treatment or no treat-
ment. Regression analyses revealed that pharmacological treatment in the past was 
predictive of both pharmacological and non-pharmacological treatments in the pre-
sent. However, use of non-pharmacological treatment in the past was uniquely pre-
dictive of its reuse in the present and future. This pattern was also accounted for by 
individual differences in pain magnification and well-being in the past.
Conclusions: Treatment preferences of FM individuals reveal an ambivalent com-
bination of heavy reliance on pharmacological treatment with lower but consistent 
reliance on non-pharmacological treatment for those individuals who used it in the 
past and present. This finding may inform longitudinal research into the relation-
ship between pharmacological and non-pharmacological treatment preference in FM 
patients, which could in turn inform guidelines for individualized therapeutic plans 
for clinicians.
Significance: Individuals with fibromyalgia reported the use of non-pharmacological 
and pharmacological treatments in the past but a predominant use of a pharmacologi-
cal approach overall. Patterns of treatment experienced in the past were differentially 
related to future preferences. Pharmacological treatment in the past was likely to lead 
to both pharmacological and non-pharmacological choices in the present. However, 
non-pharmacological treatment in the past was more likely to be chosen again in the 
present and future, but unlikely to lead to a pharmacological choice.
2 |   VALENTINI ET AL.
1 |  INTRODUCTION
According to the recent classification of chronic pain for the 
International Classification of Diseases, fibromyalgia (FM) 
is conceived as a “chronic primary pain,” namely a condition 
whereby widespread pain should be considered as the disease 
per se rather than as a symptom occurring in the context of 
an unrelated condition (Treede et al., 2019). Such diagnostic 
coding reflects the debilitating dimension of FM, a disorder 
characterized by core symptoms such as persistent and in-
tense muscle and joint pain, sleep disturbances and fatigue 
(Wolfe et al., 2010). Over the years, clinicians have attributed 
several additional symptoms to FM including cognitive 
dysfunctions, depression, anxiety and sensory disturbances 
(Wolfe et al., 2016). Estimates of the prevalence of FM range 
between 0.5% and 5% of the total population (Bernardy, 
Füber, Köllner, & Häuser, 2010; Branco et al., 2010; Jones 
et al., 2015). A more recent meta-analysis of epidemiological 
evidence suggests that 1.78% of the general population, and 
3.98% of the female population, have been diagnosed with 
FM (Heidari, Afshari, & Moosazadeh, 2017).
Treatment outcome in FM is often centred on pain reduc-
tion; however, the IMMPACT survey showed that psycho-
logical well-being is a crucial dimension to consider when 
assessing treatment effectiveness in people with chronic pain 
(Turk et al., 2008). There is evidence that both pharmacological 
and non-pharmacological treatments lead to clinically mean-
ingful improvement in FM patients (Cording, Moore, Derry, & 
Wiffen, 2015; Häuser, Urrútia, Tort, Üçeyler, & Walitt, 2013; 
Uceyler, Hauser, & Sommer, 2011). The most recent European 
League Against Rheumatism (EULAR) recommendations indi-
cate strong evidence for a beneficial effect of physical exercise 
and suggest patient education and non-pharmacological thera-
pies as initial treatment strategies and for ongoing management 
of severe cases (Macfarlane et al., 2017). These conclusions 
were supported by several findings, including large surveys 
on the US and German populations affected by FM (Bennett, 
Jones, Turk, Russell, & Matallana, 2007; Häuser et al., 2012). 
However, clinicians recognize that FM is a multifactorial condi-
tion with heterogeneous configuration across individuals (Rooij 
et al., 2013; Turk, Okifuji, Sinclair, & Starz, 1998), thus requir-
ing a biopsychosocial, multidisciplinary, personalized approach 
to be treated effectively (Häuser, Perrot, Clauw, & Fitzcharles, 
2017).
Randomized controlled trials have shown that multiple 
non-pharmacological treatments, such as psychotherapy, exer-
cise therapy, education and physiotherapy, are effective in re-
duction of FM symptoms. Importantly, cognitive behavioural 
therapy (CBT) ostensibly reduces several FM symptoms, in-
cluding pain at follow-up (Bernardy, Klose, Welsch, & Häuser, 
2018). Despite this evidence, the most prominent treatment 
strategy for the reduction of FM symptoms continues to be 
pharmacological. And yet, past surveys showed that patients 
report little satisfaction with treatment, including pharmaco-
logical therapies (Lauche et al., 2013; Robinson et al., 2013). 
Therefore, therapeutic approaches have been shifting towards a 
multi-component approach to treat the condition (Teo, Mohan, 
& Oelke, 2017). To date, however, there is little evidence that 
even a multi-component approach is effective in substantially 
reducing FM symptoms. For example, Van De Houte et al. 
(2017) recently observed that only a fourth to a third of FM 
patients assessed in the context of a multi-component treatment 
program had improvement in treatment outcomes.
The aim of the present internet-based cross-sectional sur-
vey was to investigate patterns of use of different available 
treatments in the past and present among people with FM, 
and their intention to use different treatments in the future. 
They also reported their well-being across the past, present 
and the future. In addition, we investigated the relationship of 
well-being, depression, anxiety and pain catastrophizing with 
attitude towards treatment.
2 |  MATERIALS AND METHODS
2.1 | Respondents
We contacted several FM support groups/organizations via 
e-mail and social media between July and August 2017 (or-
ganizations' names and members' nationality are reported in 
Supporting Information S1). Members of these associations 
(N  =  666) voluntarily completed an internet-based cross-
sectional survey (developed using Qualtrics, Provo, UT). 
Respondents were informed that the aim of the survey was to 
collect information about their condition and to evaluate the 
treatments they felt were most successful in reducing the im-
pact of their symptoms. Also, how likely they were to use the 
treatments in the future. They were informed that the survey 
would take approximately 20 min to complete. Respondents 
gave their informed consent before beginning the study, 
which was approved by the University of Essex ethics com-
mittee (project code EV1501).
2.2 | Survey content
The complete survey consisted of five blocks: information 
and consent, demographics and information concerning di-
agnosis, treatment choice, treatment rating, personality and 
well-being questionnaires.
2.2.1 | FM assessment
The main criterion for participation was a diagnosis of FM. 
Participants were asked “How long has it been since you were 
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diagnosed with FM?” (Table 1). We first asked respondents 
to provide us with some demographic information. They then 
completed the symptom severity (SS) and widespread pain 
index (WPI) to assess the impact of the symptoms and gener-
alized pain (Wolfe et al., 2010). Responses to these measures 
were used to screen participants for inclusion in analyses.
2.2.2 | Mood, pain catastrophizing and well-
being
Participants completed the patient health questionnaire 
(PHQ-9; Kroenke & Spitzer, 2002) to investigate the current 
disposition to depressive symptoms, and the State-Trait 
Anxiety Inventory (STAI; Spielberger et al., 1983) to assess 
anxiety. The PHQ-9 partitions overall individual scores into 
five categories: (a) minimal symptoms; (b) minor depression, 
dysthymia; (c) major depression, mild; (d) major depression, 
moderately severe; (e) major depression, severe. In addition, 
respondents completed the pain catastrophizing scale (PCS; 
Sullivan, Bishop, & Pivik, 1995), a questionnaire that meas-
ures the cognitive/emotional attitude towards pain. Lastly, 
they completed the Temporal Satisfaction with Life (TSL) 
scale (Pavot, Diener, & Suh, 1998) to quantify their well-
being in the past, present and future.
2.2.3 | Treatment preferences
Participants were presented with a list of pharmacological 
treatments, psychological interventions, physical therapy, 
physiotherapy and occupational therapy. Participants were 
asked to indicate which they had used in the past (“Since 
your diagnosis did you have any of these treatments?”), pre-
sent (“Since your diagnosis are you still having any of these 
treatments?”) and what they wished to use in the future (“Are 
you planning or thinking of using these treatments in the 
future?”).
2.3 | Data analysis approach
Data entry was checked for accuracy. Data analysis was 
performed in SPSS Statistics (IBM SPSS Statistics for 
Windows, version 22.0, IBM Corp). None of the variables 
were normally distributed. All statistics were two tailed at the 
0.05 significance level and missing values were dealt with 
casewise deletion. Bootstrap or Monte Carlo approximation 
with confidence level was calculated for each of the inferen-
tial statistics (10,000 samples).
2.3.1 | Single versus multiple 
combined treatment
Respondents could select their treatments among several op-
tions: pharmacological treatments (i.e. a series of drugs most 
frequently applied to treatment of FM symptoms), psycho-
logical interventions (i.e. a few representative psychological 
treatments), physical therapy, physiotherapy and occupational 
therapy. Moreover, respondents were given the option to 
specify alternative treatments (e.g. naturopathy and acupunc-
ture) that were not mentioned in this list, or no treatment at 
all. Each respondent could provide more than one response, 
thus permitting assessment of the difference within and be-
tween respondents in terms of multiple combined treatment 
T A B L E  1  Demographics and disease-related questions 
(N = 464)
Sample feature
N or 
Mediana % or range
Gender
Male 28 6
Female 436 94
Age 49 69
Ethnicity
Caucasian 418 90.1
Black or African American 4 0.9
Asian/ Pacific Islander 6 1.3
Hispanic or Latino 1 0.2
Other 35 7.5
Time from diagnosis
Less than 2 years 179 38.6
Less than 5 years 89 19.2
5 years or more 90 19.4
More than 10 years 106 22.8
Illness intensity rating
Severe 206 44.4
Moderate 236 50.9
Mild 22 4.7
Symptoms from diagnosis
Pain 464 100
Depression 370 79.7
Sleep disturbances 449 96.8
Anxiety 379 81.7
Fatigue 460 99.1
Cognitive dysfunctions 425 91.6
WPI score 12 16
SS score 9 12
Abbreviations: FM, fibromyalgia; SS, symptom severity score; WPI, widespread 
pain index.
aNo missing values. 
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versus single treatment across time. We calculated Friedman 
ANOVA first to assess the presence of difference in choices 
across time for all the treatment categories. Significant dif-
ferences were then further analysed using Wilcoxon matched 
pairs test.
2.3.2 | Mapping the relationship 
between treatment preference and time 
frame of the choice
Having no specific hypotheses about the direction of the re-
lationship between treatment choice and time frame of the 
choice, we explored this relationship by applying corre-
spondence analysis (CA). CA is a dimensionality reduction 
technique that allows us to describe the relationship between 
categorical data (Sourial et al., 2010). CA can also be con-
ceived as a pattern recognition method that treats nominal 
data sets in rows and columns within two-way tables as 
points on a multidimensional graphical map, also called a 
biplot (Benzecri, 1992). Akin to factor analysis or principal 
component analysis, CA aims to explain the overall inertia 
(i.e. variance) in the model with the least number of dimen-
sions. Rows with similar frequencies will have points that are 
close together in the bidimensional space. The same reason-
ing applies to columns. The objective of this analysis is to 
show the co-occurrence of the categories in a bidimensional 
space where the proximity of these categories may indicate 
meaningful associations among themselves. We expressed 
the inertia using the chi-squared statistic (i.e. weighted 
Euclidean distance) that indexes the distance between points 
on the biplot (Greenacre, 2013). We used a symmetrical nor-
malization method for a two-dimensional model explaining 
the inertia of raw points. It is noteworthy that the index of 
distance makes it possible to interpret the associations be-
tween categories of the same variable (e.g. between different 
treatments) but not between variables of different categories 
(e.g. between different treatments and temporal frames). 
However, it is possible to make interpretations of the general 
locations of row and column points, and their relations within 
each type of point.
2.3.3 | Assessing the predictive role of 
treatment preference over time
We performed multinomial logistic regression to discover 
whether the use of a non-pharmacological or pharmacologi-
cal approach in the past was predictive of present and future 
treatment preference. We separately analysed whether past 
treatment preference was predictive of present and future 
treatment preference. Therefore, three categories entered the 
analysis: pharmacological, non-pharmacological and both. 
We selected the “both” category as reference baseline as this 
was the most common approach in the past. Results are re-
ported as relative log odds and SE.
2.3.4 | Well-being and other individual 
differences
We analysed the difference in well-being scores across time 
using Friedman ANOVA. Significant differences were then 
further analysed using Wilcoxon matched pairs test. We used 
again multinomial logistic regression to explore whether any 
of the mood, anxiety, pain catastrophizing and well-being 
scores were predictive of the use of non-pharmacological or 
pharmacological treatment in the past. We then re-instated 
the models looking at the effect of (a) past on present and (b) 
present on future treatment preference by adding the mood, 
anxiety, pain catastrophizing and well-being scores as covar-
iates in separate regression analyses. Results are reported as 
relative log odds and SE.
3 |  RESULTS
3.1 | Sample demographics and FM 
symptoms
The sociodemographic and disease profile of the final sam-
ple are reported in Table 1. Respondents who did not meet 
the inclusion criterion of WPI > 7 and SS > 5 or WPI 3–6 
and SS  >  9 were excluded from the data analysis as they 
were not consistently clinically classifiable as FM patients. 
This operation led to us excluding the data from 149 re-
spondents who did not fully complete the WPI or SS and 53 
respondents whose scores did not meet the inclusion criteria 
from the whole data set of 666 respondents, thus leaving 
us with a sample of 464 respondents (69.7%). These were 
mostly white Caucasians (90.1%) with a median age of 
49  years (ranging between 16 and 85). An overwhelming 
majority of respondents were female (94%) with a mild bi-
modal pattern of diagnosis onset, being largely distributed in 
either a recent diagnosis (38.6%) or a long-standing condi-
tion (22.8%). A similar bimodal distribution was applied to 
their rating of illness intensity, showing that the respondents 
were split between a moderate and severe illness (50.9% and 
44.4%). Pain and fatigue were the most represented symp-
toms (100% and 99.1%). Nevertheless all the symptoms 
were highly represented in the sample. Both the median WPI 
and SS scores are high as expected in individuals diagnosed 
with FM even though there was a large variability in both 
scale scores.
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3.2 | Single or multiple combined 
treatment?
The treatment choice differed across time (휒2
434
  =  200.48; 
p < .001). Figure 1 shows how this difference was explained 
by higher adoption of combined treatment against single 
treatment (either pharmacological or non-pharmacological) 
in the past versus present (Z443 = −13.25; p < .001) and in 
the future prospect versus present (Z434 = −6.89; p < .001). 
However, less combined treatment was intended in the future 
compared to the past (Z434 = −6.34; p < .001).
Figure 2 describes the respondents’ choice of treatments 
in the past, present and future, while (Supporting Information 
S2: Table S1) provides more detail about the frequency with 
which specific pharmacological and psychological treatments 
have been sought. The most salient information concerns the 
amount of people adopting pharmacological treatment in the 
past (64.9%), present (55%) and planning to adopt it in the 
future (32.8%) compared to other treatments.
3.3 | Map of the relationship 
between treatment preference and time 
frame of reference
We applied CA to explore the structure of the relationship be-
tween the different type of treatments and the preference at-
tached to them in each of the temporal frames. The graphical 
representation (Figure 3) summarizes these relationships. As 
guidance for interpretation, the greater the distance between a 
type of treatment and a temporal frame the less likely is they 
are associated in accounting for the data. The CA model was 
highly significant (휒2
434
 = 217.90; p < .001). The total iner-
tia was 9.4%. Of this variance, 65.5% was accounted for by 
Dimension 1 while 34.5% was accounted for by Dimension 
F I G U R E  1  Box-plots characterizing the relationship between 
temporal frame (y axis) and treatment choice (x axis). The small 
square indicates the median, the box indicates the 25th and 75th 
percentiles and the whiskers indicate the extreme values. Note how 
most of the respondents used at least two different treatments in the 
past. Significant differences are indicated with asterisks (***p < .001). 
Abbreviations: FUT, Future; PRES, Present
F I G U R E  2  Bar chart detailing the per cent frequency of choice 
(y axis) per each treatment category (x axis) in the past (black), 
present (grey) and future (lighter grey). Note the greater preference 
for pharmacological treatment in the past and present as well as 
physiotherapy in the past. Abbreviations: FUT, Future; PRES, Present. 
PHARM, pharmacological; PSY, psychological; OCC, occupational; 
PHYSIO, physiotherapy; PHYS, physical therapy; OTHER, other 
treatment; NONE, no treatment
F I G U R E  3  Biplot representing the treatment choice (red) and 
time frame of the choice (blue). Note the three clouds clustering 
preference for psychological treatment, physiotherapy and 
occupational therapy in the past (bottom), pharmacological treatment 
in the present (top right) and other treatment or no treatment in the 
future (top left). Abbreviations: FUT, Future; PRES, Present. PHARM, 
pharmacological; PSY, psychological; OCC, occupational; PHYSIO, 
physiotherapy; PHYS, physical therapy; OTHER, other treatment; 
NONE, no treatment
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2. Supporting Information S3: Table S2 provides detail of 
row and column statistics.
Present choices (Figure 3, top right quadrant) loaded more on 
Dimension 1 (54.6%) than Dimension 2 (23.4%). Likewise, future 
choices (Figure 3, top left quadrant) loaded more on Dimension 
1 (45%) than Dimension 2 (21.7%). On the contrary, past choices 
(Figure  3, bottom right quadrant) loaded more on Dimension 
2 (54.8%) than Dimension 1 (0.4%). Overall, Dimension 1 ex-
plained 81.5% and 79.7% of present and future choices, respec-
tively, whereas the extraction of Dimension 2 explained 98.7% 
of the variance in the past choices. Concerning the treatment 
options, Dimension 1 was best contributed by pharmacological 
treatment (63%; Figure  3, top right), other treatment (17.4%; 
Figure  3, top left) and physical therapy (9.0%; Figure  3, top 
left) while Dimension 2 was best contributed by physiotherapy 
(35.7%; Figure 3, bottom left), other treatment (24.7%; Figure 3, 
top left) and no treatment (14.9%; Figure 3, top left). Dimension 
1 explained 95.7% of pharmacological treatment, 57.1% of other 
treatment and 99.9% of physical therapy, whereas the extraction 
of Dimension 2 accounted for 96% of physiotherapy, 42.9% of 
other treatment and 53.8% of no treatment.
The biplot displays an extreme distancing between phar-
macological treatment and all the other survey options along 
the x axis (red dots), particularly against other treatment, phys-
ical therapy and no treatment. Likewise, it indicates an opposi-
tion between past choices versus present and future choices on 
the y axis (blue dots). The plot also reveals three main clouds 
where Euclidean distances are nearest. A cluster on the bottom 
suggests the association of past preferences with physiother-
apy, psychological and occupational treatment (bottom right 
and left quadrant). A cluster on the top right quadrant hints to 
pharmacological treatment as the best treatment in represent-
ing present respondents’ choices. Finally, a third cluster hints 
to the association between future attitude towards treatment 
and physical therapy, other alternative treatment or no treat-
ment at all (top left quadrant). See Supporting Information 
S4 for a characterization of what alternative treatment was re-
ported by survey respondents (Table S3).
3.4 | Is the previous or current treatment 
preference predictive of subsequent choices?
Past versus Present preference. Figure  4 (left) summarizes 
the model's effects in terms of predicted probabilities. The 
model significantly explained the data (n = 312). Specifically, 
past attitude was predictive of present choices (휒2
4
 = 142.14; 
p < .001). The model correctly predicted an overall 61.5% of 
choices. The relative log odds indicate that, compared to the 
“both” category, respondents using pharmacological treat-
ment in the past were more likely to keep using it in the present 
(b = 23.06; SE = 0.56; p < .001; Figure 4, left graph, blue fit, 
left). Conversely, those using non-pharmacological treatments 
in the past were equally likely to use pharmacological treat-
ment in the present (b = 0.34; SE = 1.78; p = .59; Figure 4, left 
graph, red fit, left). Importantly, respondents using pharmaco-
logical treatment in the past were more likely to use non-phar-
macological treatment in the present (b = 19.21; SE = 9.15; 
p < .001; Figure 4, left graph, blue fit, centre). Similarly, re-
spondents using non-pharmacological treatments in the past 
were more likely to use it again in the present (b  =  2.03; 
SE = 1.65; p < .001; Figure 4, left graph, red fit, centre).
Present versus Future preference. Figure  4 (right) sum-
marizes the model's effects in terms of predicted probabil-
ities. The model significantly explained the data (n = 264; 
휒
2
4
  =  96.12; p  <  .001). The model correctly predicted an 
overall 53.4% of choices. The relative log odds indicate 
that, compared to the “both” treatment category, respon-
dents using pharmacological treatment in the present were 
equally likely to express the intention to keep using it in the 
future (b = −0.36; SE = 0.23; p = .10). Similarly, those using 
non-pharmacological treatments in the present were equally 
likely to express the intention of using pharmacological treat-
ment in the future (b = −0.18; SE = 0.61; p = .76). Crucially, 
respondents using non-pharmacological treatments in the 
present were more likely to report wanting to use it again 
in the future (b = 2.06; SE = 0.43; p < .001; Figure 4, right 
graph, red fit, centre). More detailed information on the 
F I G U R E  4  Per cent predicted probabilities (y axis) indicating how likely, compared to the “both” treatment category (grey), respondents 
were to choose pharmacological (blue) or non-pharmacological (red) treatment in the present based on past choices (left graph) or as potential 
therapy in the future based on present choices (right). Significant predictions are indicated with asterisks (*p < .001). Abbreviations: Pharm, 
pharmacological; Non-Pharm, non-pharmacological
   | 7VALENTINI ET AL.
different alternative treatments is reported in Supporting 
Information S4: Table S3.
3.5 | Mood, anxiety, catastrophizing and 
well-being estimates
Table 2 reports the central tendency and variability in scores 
of mood, anxiety, pain catastrophizing and well-being. Most 
respondents reported a mild level of depressive symptoms 
(scoring 8 of 27) and a high level of state and trait anxiety 
(scoring 50 of 60). The PCS scores were above the average 
of the normative sample (i.e. >20; Sullivan et al., 1995). 
Likewise, satisfaction with life in the past, present and future 
(TSL) was higher than the norms obtained amongst the refer-
ence student sample (Pavot et al., 1998).
In addition, Friedman ANOVA revealed that FM re-
spondents reported different levels of well-being over time 
(휒2
383
 = 24.34; p < .001). This was explained by lower well-be-
ing in the past compared to present (Z383 = −4.46; p < .001) and 
future (Z383 = −4.22; p < .001) but no difference in well-being 
between present and future (Z383 = −0.29; p = .78).
3.6 | Predictive role of mood, anxiety, 
catastrophizing and well-being estimates on 
treatment preference
We replicated the regression analysis of treatment preference 
by introducing the mood and well-being questionnaire scores 
as continuous covariates in the models.
Past versus Present preference. Pain catastrophizing and 
well-being in the past were the only covariates that had a sig-
nificant effect on the regression models. The model including 
the three pain catastrophizing subscales (n = 312) signifi-
cantly contributed to predict present choices (휒2
6
 = 137.68; 
p < .001). The model correctly predicted an overall 62.5% 
of choices. The pain magnification subscale alone explained 
the effect, with respondents reporting higher pain magni-
fication being more likely to choose non-pharmacological 
treatment in the present if they had used it already in the 
past (b = 0.44; SE = 0.13; p =  .001; Figure 5, left graph, 
red fit). The model including the well-being in the past sub-
scale (n = 281) significantly contributed to predict present 
choices (휒2
6
 = 183.38; p < .001). The model correctly pre-
dicted an overall 61.6% of choices. Respondents scoring 
lower in well-being in the past were more likely to use either 
pharmacological (b = −0.04; SE = 0.02; p = .03; Figure 5, 
right graph, blue fit) or non-pharmacological treatment in 
the present (b = −0.07; SE = 0.03; p = .03; Figure 5, right 
graph, red fit), whereas their use in combination was linked 
to greater well-being (Figure  5, reference category, both, 
grey line).
Present versus Future preference. None of the models re-
vealed a significant main effect.
4 |  DISCUSSION
The results of our cross-sectional web survey revealed a sam-
ple consisting of middle-aged, Caucasian women (Table 1) 
who had used a range of different type of treatments to allevi-
ate their FM symptoms in the past and planned to do so in the 
future (Figures 1 and 2; Table S1). Correspondence analysis 
of treatment preference across time (Figure 3; Table S2) sug-
gested a significant diversity of choice clustering whereby 
non-pharmacological treatments dominated in the past (i.e. 
psychological treatment, physiotherapy and occupational 
therapy), whereas pharmacological treatment dominated pre-
sent choices. And yet, future choices tended to emphasize 
alternative treatment or no treatment at all. Interestingly, the 
regression analysis added to the CA by revealing that non-
pharmacological choices in the past were not predictive of 
a greater likelihood to choose pharmacological treatment in 
the present (Figure 4, left graph, red fit), whereas respondents 
adopting pharmacological treatment in the past were more 
likely to use non-pharmacological treatment in the present 
(Figure  4, left graph, blue fit). Likewise, the prediction of 
future preferences based on present choices indicated that 
future scenarios were more likely involving non-pharma-
cological treatments (Figure 4, right graph, red fit) if these 
were the preferred treatment in the present (clearly involv-
ing the “other” category of alternative treatments, Supporting 
Information S4: Table S3).
T A B L E  2  Mood, anxiety, catastrophizing and well-being 
questionnaire scores
Questionnaire Mean SD
PHQ-9 8.53 4.76
STAI Y-1 50.32 2.39
STAI Y-2 56.26 8.67
PCS
Rumination 11.05 5.71
Magnification 3.13 2.34
Helplessness 13.04 6.32
Total 25.46 12.31
TSWLS*
Past 22.66 8.02
Present 24.96 8.24
Future 24.90 7.54
Total 72.52 18.77
Abbreviations: PCS, pain catastrophizing scale; PHQ-9, patient health 
questionnaire (9 items); STAI Y-1 and Y-2, State-Trait Anxiety Inventory (Y-1, 
State; Y-2, Trait; TSWLS, Temporal Satisfaction With Life Scale) (*data for 
this questionnaire rely on a partial sample of 383 respondents)
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With regard to the other subjective variables included in 
the survey, we also found respondents reported that they had 
significantly lower well-being in the past compared with their 
current state and future prospect (Table  2). The regression 
analyses revealed that the respondents reporting higher pain 
magnification were more likely to choose non-pharmacolog-
ical treatment in the present (Figure  5, left graph, red fit). 
In addition, we observed that respondents scoring lower in 
well-being in the past were more likely to equally opt either 
for pharmacological or non-pharmacological treatment in the 
present (Figure 5, right graph).
4.1 | Attitude to treatment
This study provides a detailed characterization of a sample 
of FM individuals representing a diverse FM population. In 
terms of sample demographics and FM symptoms, our find-
ings are fully compatible with the available epidemiological 
literature that indicates women outnumber men in the diag-
nosis of FM. Women are twice as likely to be diagnosed with 
the FM syndrome compared to men, with the most common 
age for the onset of the diagnosis between the ages of 25 and 
55 (Heidari et al., 2017). Additionally, in line with our study, 
previous reports indicate that most people diagnosed with 
FM are Caucasian, middle-aged women reporting pain and 
fatigue as the most common symptoms (Bennett et al., 2007; 
Häuser et al., 2012; Jones et al., 2015).
Our respondents opted for pharmacological treatment 
as well as for non-pharmacological treatment in their past. 
Significantly, our study provides even more convincing evi-
dence that FM individuals find no satisfying relief in a sin-
gle treatment therapeutic strategy, and that pharmacological 
agents do not provide enough therapeutic advantage compared 
with a non-pharmacological strategy. Crucially, our respon-
dents expressed a preference for less combined treatment in the 
future compared to the past, as well as a trend in reduction on 
reliance on pharmacological options over time (64.9% in the 
past, 55% in the present and 32.8% in the future). This trend is 
concomitant with the preference for other treatments not listed 
in our survey (i.e. OTHER; 27.4%, 11.2% and 32.5%, respec-
tively; see Supporting Information S4: Table S3). However, we 
also observed an increased number of respondents planning to 
have no further treatment in the future (14.9%) compared to 
the present (9.1%) and past (21.8%). Therefore, we may spec-
ulate that while our respondents might have not been able (or 
wanting) to rely on multiple treatments in the present as much 
as they had done in the past, they planned to opt again for a 
diversified treatment strategy in the future, or for no treatment 
at all, thus outlining an ambivalent pattern of hope and help-
lessness. Our regression analyses reinforce the presence of this 
ambivalent pattern by shedding light on the relationship be-
tween pharmacological and non-pharmacological treatments: 
respondents who had previous experience with non-pharma-
cological treatment showed a preferential trajectory towards 
non-pharmacological treatment. This preference is in agree-
ment with the EULAR recommendations (Macfarlane et al., 
2017) but strikes a contrast with the great reliance on pharma-
cological treatment overall. Crucially, these are all individuals 
who were recruited through specialized FM support groups/
organizations, and therefore perhaps educated on FM pathol-
ogy and treatment. Respondents may have found the treatment 
less effective than pharmacological treatment or they may have 
found the psychological treatment to be effective and hence 
required no further treatment. This last interpretation would 
reconcile their treatment strategy with the EULAR guidelines, 
as psychological therapy is recommended as one of the first 
treatments to newly diagnosed FM patients (Macfarlane et al., 
2017). However, it is also possible that FM individuals aban-
doned psychological therapy over time as its cost may not be 
viable, especially in the context of a combined treatment strat-
egy. After all, it is well known that FM is experienced as a 
F I G U R E  5  Per cent predicted probabilities (y axis) indicating how likely, compared to the “both” treatment category (grey), respondents 
were to choose pharmacological (blue) or non-pharmacological (red) treatment in the future based on present choices. The left graph shows the 
greater likelihood of choosing non-pharmacological treatment in the future if the respondent scored high in pain magnification. The right graph 
shows the lower likelihood of choosing either pharmacological or non-pharmacological treatment in the present if the respondent reported low 
well-being in the past (right). Significant predictions are indicated with asterisks (*p < .05). Abbreviations: Pharm, pharmacological; Non-Pharm, 
non-pharmacological
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substantial financial burden by patients (Sicras et al., 2009). 
A similar reasoning can be applied to both physiotherapy and 
physical therapies which results revealed respondents wanting 
to return to in the future.
4.2 | Mood, catastrophizing, anxiety and 
well-being
The increased frequency of choice for several different 
treatments in the future, including unlisted alternative treat-
ment, is a finding that hints to the ongoing dissatisfaction 
of our respondents with their present treatment strategy. 
This finding, combined with the high degree of mild depres-
sion symptoms and high level of state and trait anxiety re-
ported by our respondents, resonates with the most recent 
recommendations to foster individualized management 
of FM treatment (Häuser et al., 2017). The FM individu-
als who participated in our survey are representative of a 
population affected by a syndrome with intensity ranging 
from moderate to severe (cumulative 95.3%). Indeed, almost 
the entire sample was affected by all the symptoms classi-
cally associated with the FM condition such as depression 
(79.7%), anxiety (81.8%), sleep disturbances (98.8%) and 
cognitive dysfunctions (91.6%). This evidence substanti-
ates the notion that FM patients are at risk of developing 
comorbid psychological conditions (Hudson, Goldenberg, 
Pope, Keck, & Schlesinger, 1992) and psychiatric disorders 
(Fietta, Fietta, & Manganelli, 2007) compared to the healthy 
general population.
Additionally, our survey has shown that respondents had 
a very high tendency to see themselves as helpless when in 
pain, to ruminate about pain and magnify its threat.
That catastrophizing and depression are risk factors for 
several disabling long-term health outcomes such as pain se-
verity and physical disability is already an established find-
ing (Edwards, Calahan, Mensing, Smith, & Haythornthwaite, 
2011). Here we report novel evidence showing that pain 
magnification may be a big factor in determining therapeu-
tic choices in FM individuals, being associated with a higher 
probability of choosing non-pharmacological approaches in 
our sample.
The finding that lower well-being in the past was pre-
dictive of greater likelihood of the use of a single treat-
ment modality in the present (both pharmacological and 
non-pharmacological) was mirrored by the finding that 
higher past well-being was associated with a higher chance 
of adopting both treatment approaches together (Figure 5, 
right graph, grey fit). This supports the notion that engaging 
in more treatments may help patients reducing psycholog-
ical distress and facilitate a process of acceptance, which 
seems to be an important psychological dimension promot-
ing well-being in patients with pain (Van Damme, Crombez, 
Van Houdenhove, Mariman, & Michielsen, 2006; Viane 
et al., 2003).
4.3 | Limitations and future directions
The present study recruited a self-selected sample of people 
via support networks so that it was not possible to verify cli-
nician diagnosis. The current study cannot explain why the 
majority of respondents opted for pharmacological treatment. 
However, the observation that past/present preference for non-
pharmacological treatment leads to higher probability of non-
pharmacological treatment preference in the present/future 
(Figure  4), together with the overall reduction of pharmaco-
logical treatment as treatment of choosing over time (Figure 2), 
hint to the possibility that many respondents were eventually (at 
least partially) dissatisfied with the pharmacological approach. 
Because of an excessive amount of missing values among 
the effectiveness ratings (Supporting Information S5 and S6), 
we could not provide a reliable analysis of this subjective di-
mension. Certainly future studies may combine a more robust 
methodological approach, such as longitudinal data collec-
tion (i.e. several temporal estimates), with both subjective and 
clinical measures of treatment effectiveness in FM individu-
als. Longitudinal research on patient's preferences may help in 
identifying better treatments in terms of perceived efficacy at 
reducing the severity of symptoms.
Another potential limitation of this study originates 
from the sampling strategy. As we sourced our respondents 
from FM associations and groups in different nations (see 
Supporting Information S1), some sociodemographic factors 
might have injected heterogeneity in respondents’ responses. 
For example, some individuals may have preferred psycho-
logical treatment on the basis of insurance coverage provided 
by insurance companies in some countries (Häuser et al., 
2012).
Finally, we failed to introduce aerobic exercise as a de-
fault treatment option in the treatment list in our survey de-
sign. Aerobic exercise seems to improve quality of life and 
physical function as well as reducing pain (Bidonde et al., 
2017), therefore future studies should explicitly include this 
category as an item in the treatment list.
4.4 | Conclusions
This study provides a detailed characterization of a sample 
of FM individuals representing a diverse FM population. 
Our findings reveal that pharmacological treatment was the 
most common preference. However, respondents also re-
ported several treatments in the past and expressed a pref-
erence for combined treatment in the future. Importantly, 
our analyses also indicate that overall the use of both 
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pharmacological and non-pharmacological treatments 
was predictive of later adoption of non-pharmacological 
treatment but also that the choice of non-pharmacological 
treatment in the past did not predict preference for phar-
macological treatment in the present. Altogether, this am-
bivalent pattern emphasizes the importance of educating 
medical professionals on the complexity of this condition 
as well as supporting patients in their therapeutic choices 
and disease management within the context of a treatment 
roadmap (Culpepper, 2012).
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